2 completed, 1 enrolling by invitation, 1 not yet recruiting, 1 terminated. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Enrolling by invitation 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Leigh Syndrome: new trials by email Literature Review of Leigh Syndrome trials Research Report on Leigh Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS) TTI-0102: cysteamine-pantetheine disulfide, D-Mannitol - Leigh Syndrome | Phase 2 | Not yet recruiting | Thiogenesis Therapeutics, Inc. | 18 | 2026-10-01 | 2026-07-24 |
| Sirolimus for Leigh Syndrome Sirolimus - Leigh Syndrome | Phase 2 | Enrolling by invitation | Matthew Demczko | 15 | 2025-02-27 | 2026-03-31 |
| ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome ABI-009 - Leigh Syndrome | Phase 2 | Withdrawn | Aadi Bioscience, Inc. | 2022-04-30 | 2022-02-01 | |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome EPI-743 - Leigh Syndrome | Phase 2 | Completed | PTC Therapeutics | 30 | 2014-01-31 | 2024-10-23 |
| Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome Placebo, EPI-743 15 mg/kg, EPI-743 5 mg/kg - Leigh Syndrome | Phase 2 | Completed | PTC Therapeutics | 35 | 2012-10-31 | 2020-08-31 |
Leigh Disease (6) · Mitochondrial Diseases (3) · Diffuse Cerebral Sclerosis of Schilder (1) · Drug Resistant Epilepsy (1) · MELAS Syndrome (1) · MERRF Syndrome (1) · Mitochondrial encephalopathy (1) · Nerve Degeneration (1) · Pontocerebellar Hypoplasia Type 6 (1) · Seizures (1) · Status Epilepticus (1)
Brain Diseases (6) · Brain Diseases, Metabolic (6) · Brain Diseases, Metabolic, Inborn (6) · Carbohydrate Metabolism, Inborn Errors (6) · Central Nervous System Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Metabolic Diseases (6) · Metabolism, Inborn Errors (6) · Nervous System Diseases (6) · Nutritional and Metabolic Diseases (6) · Pyruvate Metabolism, Inborn Errors (6) · Mitochondrial Diseases (3) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1)
alpha-tocotrienol quinone (3) · Mannitol (1) · Sirolimus (1) · cysteamine-pantetheine disulfide (1)
PTC Therapeutics (3) · Aadi Bioscience, Inc. (1) · Matthew Demczko (1) · Thiogenesis Therapeutics, Inc. (1)
United States (4) · Canada (1) · France (1) · Italy (1) · Japan (1) · Poland (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Bruce Cohen, MD (1) · Matthew Demczko, MD (1) · Patrice Rioux, MD, PhD (1) · Vinay Penematsa, MD (1) · Zarazuela Zolkipli-Cunningham, MBChB, MRCP (1)